1098 related articles for article (PubMed ID: 32890967)
21. Liu Shen capsule shows antiviral and anti-inflammatory abilities against novel coronavirus SARS-CoV-2 via suppression of NF-κB signaling pathway.
Ma Q; Pan W; Li R; Liu B; Li C; Xie Y; Wang Z; Zhao J; Jiang H; Huang J; Shi Y; Dai J; Zheng K; Li X; Yang Z
Pharmacol Res; 2020 Aug; 158():104850. PubMed ID: 32360580
[TBL] [Abstract][Full Text] [Related]
22. In silico study of azithromycin, chloroquine and hydroxychloroquine and their potential mechanisms of action against SARS-CoV-2 infection.
Braz HLB; Silveira JAM; Marinho AD; de Moraes MEA; Moraes Filho MO; Monteiro HSA; Jorge RJB
Int J Antimicrob Agents; 2020 Sep; 56(3):106119. PubMed ID: 32738306
[TBL] [Abstract][Full Text] [Related]
23. ACE2, TMPRSS2 distribution and extrapulmonary organ injury in patients with COVID-19.
Dong M; Zhang J; Ma X; Tan J; Chen L; Liu S; Xin Y; Zhuang L
Biomed Pharmacother; 2020 Nov; 131():110678. PubMed ID: 32861070
[TBL] [Abstract][Full Text] [Related]
24. Propolis, Bee Honey, and Their Components Protect against Coronavirus Disease 2019 (COVID-19): A Review of In Silico, In Vitro, and Clinical Studies.
Ali AM; Kunugi H
Molecules; 2021 Feb; 26(5):. PubMed ID: 33669054
[TBL] [Abstract][Full Text] [Related]
25. PI3Kδ Inhibition as a Potential Therapeutic Target in COVID-19.
Palma G; Pasqua T; Silvestri G; Rocca C; Gualtieri P; Barbieri A; De Bartolo A; De Lorenzo A; Angelone T; Avolio E; Botti G
Front Immunol; 2020; 11():2094. PubMed ID: 32973818
[TBL] [Abstract][Full Text] [Related]
26. SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor.
Hoffmann M; Kleine-Weber H; Schroeder S; Krüger N; Herrler T; Erichsen S; Schiergens TS; Herrler G; Wu NH; Nitsche A; Müller MA; Drosten C; Pöhlmann S
Cell; 2020 Apr; 181(2):271-280.e8. PubMed ID: 32142651
[TBL] [Abstract][Full Text] [Related]
27. Ivermectin, antiviral properties and COVID-19: a possible new mechanism of action.
Rizzo E
Naunyn Schmiedebergs Arch Pharmacol; 2020 Jul; 393(7):1153-1156. PubMed ID: 32462282
[TBL] [Abstract][Full Text] [Related]
28. SARS, MERS and SARS-CoV-2 (COVID-19) treatment: a patent review.
Nascimento Junior JAC; Santos AM; Quintans-Júnior LJ; Walker CIB; Borges LP; Serafini MR
Expert Opin Ther Pat; 2020 Aug; 30(8):567-579. PubMed ID: 32429703
[TBL] [Abstract][Full Text] [Related]
29. Remdesivir against COVID-19 and Other Viral Diseases.
Malin JJ; Suárez I; Priesner V; Fätkenheuer G; Rybniker J
Clin Microbiol Rev; 2020 Dec; 34(1):. PubMed ID: 33055231
[TBL] [Abstract][Full Text] [Related]
30. Discovering small-molecule therapeutics against SARS-CoV-2.
Tiwari V; Beer JC; Sankaranarayanan NV; Swanson-Mungerson M; Desai UR
Drug Discov Today; 2020 Aug; 25(8):1535-1544. PubMed ID: 32574699
[TBL] [Abstract][Full Text] [Related]
31. 3C-like protease inhibitors block coronavirus replication in vitro and improve survival in MERS-CoV-infected mice.
Rathnayake AD; Zheng J; Kim Y; Perera KD; Mackin S; Meyerholz DK; Kashipathy MM; Battaile KP; Lovell S; Perlman S; Groutas WC; Chang KO
Sci Transl Med; 2020 Aug; 12(557):. PubMed ID: 32747425
[TBL] [Abstract][Full Text] [Related]
32. In Silico Insights into the SARS CoV-2 Main Protease Suggest NADH Endogenous Defences in the Control of the Pandemic Coronavirus Infection.
Martorana A; Gentile C; Lauria A
Viruses; 2020 Jul; 12(8):. PubMed ID: 32722574
[TBL] [Abstract][Full Text] [Related]
33. Chloroquine does not inhibit infection of human lung cells with SARS-CoV-2.
Hoffmann M; Mösbauer K; Hofmann-Winkler H; Kaul A; Kleine-Weber H; Krüger N; Gassen NC; Müller MA; Drosten C; Pöhlmann S
Nature; 2020 Sep; 585(7826):588-590. PubMed ID: 32698190
[TBL] [Abstract][Full Text] [Related]
34. Novel Drugs Targeting the SARS-CoV-2/COVID-19 Machinery.
Sternberg A; McKee DL; Naujokat C
Curr Top Med Chem; 2020; 20(16):1423-1433. PubMed ID: 32416679
[TBL] [Abstract][Full Text] [Related]
35. Analysis of the molecular mechanism of Pudilan (PDL) treatment for COVID-19 by network pharmacology tools.
Kong Q; Wu Y; Gu Y; Lv Q; Qi F; Gong S; Chen X
Biomed Pharmacother; 2020 Aug; 128():110316. PubMed ID: 32505821
[TBL] [Abstract][Full Text] [Related]
36. Potential therapeutic effects of Resveratrol against SARS-CoV-2.
Ramdani LH; Bachari K
Acta Virol; 2020; 64(3):276-280. PubMed ID: 32985211
[TBL] [Abstract][Full Text] [Related]
37. Roles of flavonoids against coronavirus infection.
Russo M; Moccia S; Spagnuolo C; Tedesco I; Russo GL
Chem Biol Interact; 2020 Sep; 328():109211. PubMed ID: 32735799
[TBL] [Abstract][Full Text] [Related]
38. Potential inhibitors of the interaction between ACE2 and SARS-CoV-2 (RBD), to develop a drug.
Benítez-Cardoza CG; Vique-Sánchez JL
Life Sci; 2020 Sep; 256():117970. PubMed ID: 32553928
[TBL] [Abstract][Full Text] [Related]
39. Anti-SARS-CoV-2 Potential of Artemisinins In Vitro.
Cao R; Hu H; Li Y; Wang X; Xu M; Liu J; Zhang H; Yan Y; Zhao L; Li W; Zhang T; Xiao D; Guo X; Li Y; Yang J; Hu Z; Wang M; Zhong W
ACS Infect Dis; 2020 Sep; 6(9):2524-2531. PubMed ID: 32786284
[TBL] [Abstract][Full Text] [Related]
40. Immune-Boosting, Antioxidant and Anti-inflammatory Food Supplements Targeting Pathogenesis of COVID-19.
Mrityunjaya M; Pavithra V; Neelam R; Janhavi P; Halami PM; Ravindra PV
Front Immunol; 2020; 11():570122. PubMed ID: 33117359
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
